TITLE

Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure

AUTHOR(S)
Dao, Doan; Seremba, Emmanuel; Ajmera, Veeral; Sanders, Corron; Hynan, Linda; Lee, William
PUB. DATE
May 2012
SOURCE
Digestive Diseases & Sciences;May2012, Vol. 57 Issue 5, p1349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and Aims: The efficacy of nucleoside(tide) analogues (NA) in the treatment of acute liver failure due to hepatitis B virus (HBV-ALF) remains controversial. We determined retrospectively the impact of NAs in a large cohort of patients with HBV-ALF. Methods: The US Acute Liver Failure Study Group, a 23-site registry, prospectively enrolled 1,413 patients with ALF with different etiologies between 1998 and 2008. Of those, 105 patients were identified as HBV-ALF patients, of whom we excluded those without data on NA use or with co-infection with hepatitis C, leaving 85 patients, 43 of whom had received NA treatment. HBV-DNA on admission was quantified by real time polymerase chain reaction. Results: The treated and untreated groups were similar in most respects but differed significantly in regard to higher aminotransferase and bilirubin levels and hepatic coma grades, all being observed in the untreated group. Median duration of NA treatment was 6 days (range, 1-21 days). Overall survival in the NA treated and untreated groups were 61 and 64%, respectively ( P = 0.72). Rates of transplant-free survival were 21 and 36% in the treated and untreated groups, respectively ( P = 0.42). Multivariate analysis revealed that not using a NA [odds ratio (OR) 4.4, 95% CI 1.1-18.1, P = 0.041], hepatic coma grade I or II [OR 14.4, 95% CI 3.3-62.8, P < 0.001] and prothrombin time (PT) [OR 0.59, 95% CI 0.39-0.89, P = 0.012] were predictors of improved transplant-free survival. Conclusions: Patients who are admitted with established HBV-ALF do not appear to benefit from viral suppression using nucleoside(tide) analogues presumably because of rapid disease evolution and short treatment duration. Despite the lack of benefit, NAs should still be given to transplantation candidates since viral suppression prevents recurrence after grafting.
ACCESSION #
74465123

 

Related Articles

  • Nucleoside Analogs as Anti-HBV Agents. Xiao-Xiong Zhou; Littler, Eddy // Current Topics in Medicinal Chemistry;May2006, Vol. 6 Issue 9, p851 

    Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of...

  • Lamivudine Therapy for Spontaneously Occurring Severe Acute Exacerbation in Chronic Hepatitis B Virus Infection: A Preliminary Study. Tsubota, Akihito; Arase, Yasuji; Saitoh, Satoshi; Kobayashi, Masahiro; Suzuki, Yoshiyuki; Suzuki, Fumitaka; Chayama, Kazuaki; Murashima, Naoya; Ikeda, Kenji; Kobayashi, Mariko; Kumada, Hiromitsu // American Journal of Gastroenterology;Feb2001, Vol. 96 Issue 2, p557 

    OBJECTIVE: The nucleoside analogue lamivudine, a potent inhibitor of hepatitis B virus replication, has shown notable results in treating chronic hepatitis B. However, lamivudine has not been specifically tested for effectiveness against spontaneously occurring severe acute exacerbations of...

  • Non-A, Non-B Fulminant Hepatitis is also Non-E and Non-C. Kuwada, Scott K.; Patel, Vinaychandra M.; Hollinger, F. Blaine; Lin, H. J.; Yarbough, Patrice O.; Wiesner, Russell H.; Kaese, Dorothy; Rakela, Jorge // American Journal of Gastroenterology;Jan1994, Vol. 89 Issue 1, p57 

    Objectives: to define the roles of the hepatitis C and E viruses (HCV and HEV) in non-A, non-B (NANB) fulminant hepatitis. Methods: we utilized the polymerase chain reaction to amplify HCV and HEV RNA sequences and assays to detect antibodies to HCV and HEV in the acute phase...

  • HBY, HCV, and TTY detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. Comar, M.; Molin, G. Dal; D'Agaro, P.; Crocë, S. L.; Tiribelli, C.; Campello, C. // Journal of Clinical Pathology;May2006, Vol. 59 Issue 5, p526 

    Objective: To report a retrospective analysis on the presence of hepatitis B virus (HBV), hepatitis C virus (HCV), and transfusion transmitted virus (TTV) sequences in formalin fixed, paraffin embedded liver biopsies from eight patients with hepatocellular carcinoma, in comparison with blood...

  • Occult Hepatitis B Virus Among the Patients With Abnormal Alanine Transaminase. Makvandi, Manoochehr; Neisi, Niloofar; Khalafkhany, Davod; Makvandi, Kamyar; Hajiani, Eskandar; Akbar Shayesteh, Ali; Masjedi Zadeh, Abdolrahim; Hosein Sina, Amir; Hamidifard, Mojtaba; Rasti, Mojtaba; Aryan, Ehsan; Ahmadi, Kambiz; Yad Yad, Mohammad Jafar // Jundishapur Journal of Microbiology;Aug2014, Vol. 7 Issue 8, p1 

    Background: The occult hepatitis B infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the sera or in the liver biopsy and the absence of hepatitis B surface antigen (HBsAg) by serological test. Objectives: The current study aimed to evaluate the occult HBV infection by...

  • Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen. Wang, Yuan Min; Ng, Wee Chit; Lo, Su Kong // Journal of Gastroenterology;1999, Vol. 34 Issue 5, p600 

    Abstract: Hepatitis B virus (HBV) with various mutations has been reported. The frequency of the natural occurrence of such variants and whether the heterogeneity of these genomic regions correlates with a specific serologic pattern of concurrent hepatitis B surface antigen (HBsAg) and hepatitis...

  • Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir. Walsh, Ann W.; Langley, David R.; Colonno, Richard J.; Tenney, Daniel J. // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: Entecavir (ETV) is a deoxyguanosine analog competitive inhibitor of hepatitis B virus (HBV) polymerase that exhibits delayed chain termination of HBV DNA. A high barrier to entecavir-resistance (ETVr) is observed clinically, likely due to its potency and a requirement for multiple...

  • Effects of two novel nucleoside analogues on different hepatitis B virus promoters. Xing-Xing He; Ju-Sheng Lin; Ying Chang; Ying-Hui Zhang; Yan Li; Xiao-Yan Wang; Dong Xu; Xiao-Ming Cheng; Ghisetti, Valeria // World Journal of Gastroenterology;3/28/2008, Vol. 14 Issue 12, p1836 

    AIM: To explore the effects of the nucleoside analogues β-L-D4A and β-LPA on hepatitis B virus (HBV) promoters. METHODS: Four HBV promoters were amplified by polymerase chain reaction (PCR) and subcloned into the expression vector pEGFP-1. The four recombinants controlled by HBV promoters...

  • Dengue causing fulminant hepatitis in a hepatitis B virus carrier. Agarwal, Mukul P.; Giri, Subhash; Sharma, Vishal; Roy, Ujjawal; Gharsangi, Komal // BioScience Trends;Feb2011, Vol. 5 Issue 1, p44 

    Dengue is an acute febrile illness resulting from infection by a flavivirus transmitted by the Aedes mosquito. It is characterized by bleeding manifestations and a plasma leak syndrome. Hepatic involvement in the form of elevation in transaminases is common. However, acute hepatic failure is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics